GenSight Biologics 소유권

주요 주주는 누구이며 내부자가 매수 또는 매도한 적이 있나요?

최근 내부자 거래

내부자 구매: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

주식의 희석: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 132.8%.

상위 13 주주가 회사의 77.88%를 소유하고 있습니다.

소유권	이름	공유	현재 값	변경 %	포트폴리오 %
25.3%	Heights Capital Management, Inc.	27,160,703	€8.3m	0%	3.73%
17.2%	Sofinnova Partners SAS	18,484,727	€5.7m	39.4%	3.76%
12.1%	Artal Group S.A.	12,973,492	€4.0m	55.1%	0.1%
7.3%	UPMC Enterprises	7,829,251	€2.4m	49%	데이터 없음
4.97%	Goldman Sachs Group, Investment Banking and Securities Investments	5,325,415	€1.6m	0%	데이터 없음
3.41%	Armistice Capital LLC	3,658,000	€1.1m	-41.9%	0.03%
2.24%	Bpifrance Participations SA	2,399,681	€736.7k	0%	0.01%
1.97%	3SBio Inc.	2,110,595	€648.0k	0%	데이터 없음
1.39%	Amiral Gestion	1,496,000	€459.3k	0%	0.03%
1.22%	Abingworth LLP	1,308,521	€401.7k	0%	0.16%
0.65%	Gensight Biologics S.A,. Employee Stock Ownership Plan	700,500	€215.1k	1,230%	데이터 없음
0.04%	FMR LLC	43,366	€13.3k	0%	데이터 없음
0.04%	Saint Olive Gestion	42,500	€13.0k	0%	데이터 없음